April 26, 2018 10:18 AM EDT

Achaogen earns $12M award for next-gen antibiotics; Endo acquires Somerset for $190M

Amber Tong

→ Antibacterial R&D accelerator CARB-X has granted Achaogen $AKAO an award worth up to $12 million to fuel its early-stage programs in for multi …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Achaogen earns $12M award for next-gen antibiotics; Endo acquires Somerset for $190M

Amber Tong

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Achao­gen earns $12M award for next-gen an­tibi­otics; En­do ac­quires Som­er­set for $190M

Amber Tong

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Achaogen earns $12M award for next-gen antibiotics; Endo acquires Somerset for $190M

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial